Straits Times Index
3,183.76 +29.07 (+0.92%) Nikkei
38,000.01 +38.21 (+0.10%) Hang Seng
16,379.42 +127.58 (+0.79%) FTSE 100
7,847.99 +27.63 (+0.35%) Bitcoin USD
61,506.73 -2,346.70 (-3.68%) CMC Crypto 200
885.54 0.00 (0.00%)
LLY Jun 2024 360.000 call
| Previous close | 398.00 |
| Open | 400.25 |
| Bid | 390.95 |
| Ask | 395.50 |
| Strike | 360.00 |
| Expiry date | 2024-06-21 |
| Day's range | 398.00 - 400.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 109 |
- Yahoo Finance Video
Eli Lilly's weight loss drug could help sleep apnea patients
Shares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial of GLP-1 its weight loss drug Zepbound. The trial revealed that the drug helped patients with sleep apnea, a condition characterized by irregular breathing during sleep. The company is now moving to apply for an expanded label from the US Food and Drug Administration (FDA). If approved, it would allow Zepbound to be prescribed and used for the treatment of sleep apnea, in addition to its current weight loss use. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Angel Smith
ZacksTop Research Reports for Eli Lilly, Linde & Caterpillar
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN) and Caterpillar Inc. (CAT).
BenzingaEli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show
Wednesday, Eli Lilly And Co (NYSE:LLY) released topline results from SURMOUNT-OSA phase 3 trials of tirzepatide in obstructive sleep apnea (OSA), a sleep-related breathing disorder characterized by complete or partial collapses of the upper airway during sleep. The data showed that tirzepatide significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. Also Read: Eli Lilly Suffer
